Most observers blame declining R&D productivity—bigger spending, fewer results—for the drug industry's woes. The latest estimates from industry consultants Bain & Co. put the cost of developing a new drug at $1.7 billion, largely due to an increasing number of clinical failures. (See "Rebuilding Big Pharma's Business Model," IN VIVO, November 2003 Also see "Rebuilding Big Pharma's Business Model" - In Vivo, 1 November, 2003..) Average return on investment: about 5%, lower than the cost of capital.
But analysts at CSFB in London argue that this view of R&D productivity oversimplifies the issues and obscures the reality...


